{"id":53075,"date":"2023-03-06T16:46:44","date_gmt":"2023-03-06T11:16:44","guid":{"rendered":"https:\/\/corpbiz.io\/learning\/?p=53075"},"modified":"2023-03-06T16:46:45","modified_gmt":"2023-03-06T11:16:45","slug":"challenges-faced-in-drug-device-combination-products","status":"publish","type":"post","link":"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/","title":{"rendered":"Challenges Faced In Drug Device Combination Products"},"content":{"rendered":"\n<p>Therapeutic and\/or diagnostic\ngoods that combine pharmaceuticals and medical devices are known as\n&#8220;combination products,&#8221; and their rising complexity has created new\nregulatory framework issues. A combination product needs to be categorized\naccording to its primary mode of action in order to be sold (PMOA). But with\nthe advancement in the technology and research sector, innovative combination\ngoods have been created that lack a definite PMOA, highlighting the absence of\na systematization process and making it difficult to classify these products\ncorrectly. Drug-Device Combination products are produced when two previously\nindependent components &#8211; drugs and medical devices &#8211; come together. A drug-led\ncombination product is essentially a drug source and a drug delivery mechanism\n(device) that delivers the medication to the patient\u2019s body for therapeutic or\ndiagnostic reasons. Drug delivery devices have a number of benefits, such as\nincreasing adherence to medication regimens, enabling localized delivery,\nfostering patient centricity and satisfaction, generating intellectual property\nthat can be used to distinguish a drug product in a crowded market, and\nultimately spurring innovation that improves public health.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title ez-toc-toggle\" style=\"cursor:pointer\">Page Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#What_Are_Combination_Products\" >What Are Combination Products?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#What_Four_Types_Of_Combo_Products_Are_There\" >What Four Types Of Combo Products Are There?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#What_Are_Some_Instances_Of_Combined_Medical_Devices\" >What Are Some Instances Of Combined Medical Devices?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#What_Is_The_PMOA_For_The_Combination_Product\" >What Is The PMOA For The Combination Product?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#Essential_Factors_to_Know_In_Case_Of_Combination_Products\" >Essential Factors to Know In Case Of Combination Products<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#Challenges_Faced_In_Drug_Device_Combination_Products\" >Challenges Faced In Drug Device Combination Products<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#Solutions_and_Recommendations\" >Solutions and Recommendations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/corpbiz.io\/learning\/challenges-faced-in-drug-device-combination-products\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Are_Combination_Products\"><\/span>What Are Combination Products?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Combination products are\ndescribed as treatments that combine two or more regulated and sold items\n(drug\/device, biologics\/device, biologics\/drugs, or drug\/device\/biologics).\nThese kind of products are therapeutic and\/or diagnostic items that combines\nmedications with medical equipment. They can also be combinations of\nmedications and biologics or medications and devices. As a significant and\nexpanding element of the therapeutic landscape, these items are regarded as\nessential to healthcare. Depending on their primary mechanism of action, drug-device\ncombinations (DDC) are either governed by Regulation (EU) 2017\/745 or by\nDirective 2001\/83\/EC (PMOA). However, novel complex goods lack a clearly\ndefined PMOA, emphasizing the difficulty in classifying combination products\ndue to the lack of systematization.<\/p>\n\n\n\n<p>Borderline items cannot be\ncombined with other products. Borderline products are complex healthcare items\nfor which it is unclear which regulatory framework should be used. These items\ninclude cosmetics, biocidal goods, herbal remedies, and food supplements in\naddition to pharmaceuticals and <strong><a class=\"text-primary\" href=\"https:\/\/corpbiz.io\/medical-device-registration\">medical devices<\/a><\/strong>. Consequently, a combination\nproduct may represent a case that is on the boundary, however combination\nproducts are not always borderline items. Additionally, single entity or\nintegral combination products and pharmaceuticals with co-packaged or referred\ndevices are two categories of combination products that differ dependent on the\nform of packaging. The former comprises of discrete things, which may or may\nnot be present in the same pack, whereas the latter is made up of components\nthat work together to create a single integrated product (such as patches for\ntransdermal drug delivery).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Four_Types_Of_Combo_Products_Are_There\"><\/span>What Four Types Of Combo Products Are There?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There are four primary\ncategories for combination products: a product comprising of two or more\nregulated components (i.e., drug\/device, biologic\/device, drug\/biologic, or\ndrug\/device\/biologic) that are physically, chemically, or otherwise combined or\nblended and created as a single entity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Are_Some_Instances_Of_Combined_Medical_Devices\"><\/span>What Are Some Instances Of Combined Medical Devices?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prefilled syringes, pen\ninjectors, auto-injectors, inhalers, transdermal pumps and patches, and kits\nwith drug delivery components or devices are a few examples of combination\nitems.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_The_PMOA_For_The_Combination_Product\"><\/span>What Is The <em>PMOA<\/em> For The Combination Product?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The primary therapeutic\nelement that focuses on the combination product\u2019s intended purpose is the PMOA.\nThe PMOA, for instance, refers to the device\u2019s capacity to open a diseased\nartery in a drug-eluting stent. The medicine acts as an \u201caid\u201d by supplying a supplementary\nPMOA. The FDA\u2019s Center for Devices and Radiological Health (CDRH), which\nregulates and clears medical devices, is anticipated to receive this product\u2019s\nsubmission. The primary FDA centre in this situation would be the Center for\nDrug Evaluation and Research (CDER), if the PMOA is connected to a medication\ncomponent of a drug\/device product. The designated reviewing agency may or may\nnot participate in the registered facilities\u2019 cGMP\/PAI inspections.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Essential_Factors_to_Know_In_Case_Of_Combination_Products\"><\/span>Essential Factors to Know In Case Of Combination Products<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Few key factors that is\nessentially to be kept in mind in case of combination products:<\/p>\n\n\n\n<ul><li>Maintaining\nthe integrity and quality of the medication, <\/li><li>Adhering\nto regulatory standards and guidelines, <\/li><li>Taking\ninto account user needs and human factors, containment, and<\/li><li>Delivery\/administration\nmodality should all be top priorities when assessing challenges that have an\nimpact on the development of combination products.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Challenges_Faced_In_Drug_Device_Combination_Products\"><\/span>Challenges Faced In Drug Device Combination Products<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The development and delivery of\ncombination medications face many of the same obstacles as the development and\nadministration of individual therapies, but the intrinsic complexity of such\nproducts increases the possibility of dangers. Some of the typical difficulties\ninclude:<\/p>\n\n\n\n<ol><li>The regulatory environments around the world are intricate and dynamic, making it challenging to feel fully educated on the most recent rules and recommendations, especially when it comes to combination products. In fact, a customer study by West found that the complex regulatory environment is frequently the biggest obstacle faced by pharmaceutical businesses when developing combination products. Since the final rule on the 21 CFR Part 4 requirements for current good manufacturing practices (cGMP) for combination products was published in January 2013, numerous draft guidance documents and other regulations have been introduced, including the EU Medical Device Regulations (MDR), which will go into effect in 2020. For many of our customers, keeping up with and adapting to these changes is a substantial and frequent challenge.<br>The regulatory definitions for medical devices and combination goods differ similarly, and it might be difficult to understand these distinctions. Definitions and terminology must be understood in order for the development team to stay on the same page while launching a combo product.<\/li><\/ol>\n\n\n\n<ul><li>Device issues, such as those resulting from a mismatch between the development of the medicine and the device or the packaging, might hinder the functionality of the final product. The dependability and sturdiness of a device used as the delivery vehicle, in addition to any other packaging components, determines in significant part whether a patient will receive a medication that is correct and safe.<br>Extensive environmental and human factors testing must be done as part of the testing required in discovering and addressing device difficulties. For combination products, the interaction between a gadget and a medicine is crucial. Drug and device manufacturers must collaborate closely from the beginning of the development process onward in order to fully and precisely understand how one component affects the other. This will help to ensure that the right materials and administration mechanisms are used.<\/li><li>Since\nlarger doses (by volume or size) can attract more difficulties, drug volume is\nanother important device issue. A relatively new idea, patient\nself-administration of higher volume, higher viscosity systems has prompted the\nneed for systems that can accommodate accordingly. However, keeping up with the\nevolving demands can be challenging. The impact of the drug on the device or\nvice versa must be taken into account while creating drug device combination\nproducts. The correct combination of components and the essential interfaces\ncan have a significant impact on the development process. The drug device\ncombination product discussion challenge should be identified, assessed, and\nstabilized at an early stage of development.<\/li><li>Optimized\n&amp; Consistent Product Integrity &amp; Quality are dependent on a wide range\nof variables that might be challenging to manage or mitigate. With combination\nproducts, the relationship between drug delivery systems and containers is even\nmore intricate. All the resources expended to get a patient\u2019s hands on a\nnecessary medication are, at best, for nothing if the quality is compromised,\nand, at worst, patients may be put at risk.<\/li><li>A\nlot of misrepresentation has been created, depending on several regulatory and\nadministrative definitions. It is pertinent to understand the importance of\nterms and meaning of the drugs device combination products while marketing in\norder to maintain compatibility in the market. Different countries have\ndifferent standards and measures for the process of submission which is unique\nin their way. When a drug device combination product is to be made available by\nthe device manufacturer they must be aware of all the implied rules and\nstandards applicable in each region. <\/li><li>In\norder to develop the regulatory and product improvement framework device\nmanufacture needs a classified primary mode of action which is to be applied in\na correct form, maintaining all standards of regulation for this products.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Solutions_and_Recommendations\"><\/span>Solutions and Recommendations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ol><li>Pharmaceutical and device firms operating in the combination goods market frequently encounter the aforementioned difficulties. Fortunately, effective testing and control, streamlined development processes, and synergistic success-oriented behaviors make real solutions achievable.<\/li><li>In a constantly shifting environment, it\u2019s critical to encourage creativity by carefully considering the final goal. This entails starting the development process with a thorough grasp of the user and patient demands as well as the profile of the drug target product, and having processes in place to keep them in mind.<\/li><li>This requires planning and readiness from a risk management perspective, including putting policies and processes in place to recognize risks, anticipate and examine potential roadblocks, mitigate and manage risk, and monitor and measure outcomes.<\/li><li>Recent innovation is beginning to change the possibilities with wearable devices that deliver medication subcutaneously, specifically to address issues with patient-administered combination medications with greater drug volumes. As the kind and amount of pharmaceuticals vary, manufacturing and packaging issues for combination products will also alter, but methods that promote patient-centered care continue to advance.<\/li><li>Above all, it is impossible to create and administer remedies to patients in a vacuum. To ensure alignment across health, strategic and tactical priorities, visions, and goals, all involved parties &#8211; those creating the medicine(s), those creating the packaging, and those tasked with administration (be they healthcare professionals, patients, or caregivers &#8211; must work together with cooperation and transparency). This, an integrated strategy can result in a solution that gets beyond a variety of difficulties unique to the development and delivery of combined products. To deliver a hybrid product, an integrated solutions programme is put in place. In a single sourced solution, this method combines our core packaging, device, analytical testing, regulatory advice, and contract manufacturing capabilities. One method that producers are assisting patients with adherence is through connected devices. Additionally, these interconnected devices are giving doctors a greater insight of how patients are utilizing a therapy. Device development is getting more and more important. According to experts, the technologies of the future that will be most successful are those that offer additional benefits outside the product itself.<\/li><li>Understanding and staying current with pertinent governance, which covers a wide range of devices and containers, is crucial from a regulatory standpoint. Drug firms can and frequently do seek advice and feedback from the device maker or supplier, especially when filing. We continue to develop our knowledge and abilities to assist customers not only in navigating the international regulations that have an impact on the development of combination products, but also in designing and carrying out the studies required to prove necessary compliance from development through and after commercialization.<\/li><li>Device and packaging manufacturers must collaborate with customers to improve their comprehension of current laws and guidelines in order to develop, carry out, and interpret appropriate study designs that cover syringes, cartridges, vials, and all associated parts and equipment. Drugs and devices that are manufactured separately for individual product is quite different from the steps taken when it is done in a collaborative and synchronized manner for the combination products.<\/li><li>Rigorous testing that aims to identify and reduce risks, adheres to standards, and concentrates on continuity is necessary to consistently produce and deliver the highest quality medicine(s) and devices. This will ultimately enable the long-term, safe, and effective delivery of drug products to patients.<br>Rigid and complicated testing is necessary to guarantee that a product\u2019s quality and integrity are upheld from conception to delivery, from extractible and particle analyses through product purity and stability. When possible, testing to measure these factors should be done in accordance with industry standards; alternatively, in situations where specific standards are still lacking for a given combination, testing should be based on related standards and take into account all of the crucial aspects of the drug preparation and delivery process.<\/li><li>Design verification studies for combination products can include and concentrate on risk reduction, adherence to established standards and regulatory requirements\/guidances, and the evaluation of physical aspects of device component performance. They can also evaluate physiochemical interactions with the drug product. Highest quality and quickly approved\/marketed products are the end result when correctly carried out. Verification testing for combination products also ensures that a device has been correctly built, operates as intended, and delivers consistently against external elements unique to the patient group for which it is intended as well as drug requirements. Additionally, it assesses the product\u2019s integrity under the most adverse circumstances, including drops, sharp temperature changes, and moisture exposure. Additionally, it\u2019s important to carefully consider where and how end users engage with a gadget in order to assess its reliability. <br>The legal structure and oversight that control the creation, production, and marketing of combination products are referred to as regulation. For patients, it is important to guarantee their safety, effectiveness, and quality. Pre-market approval is often required by governments, and it entails significant testing and clinical trials. Additionally, regulations outline labelling specifications and post-market surveillance, which entails continuous product inspection for safety concerns and the potential for product recalls or other regulatory action. Combination product regulation is intricate and multidisciplinary, combining both technological and medical expertise to guarantee the highest standards. The regulation of these products is heavily influenced by organizations like the European Medicines Agency and <strong>the U.S. Food and Drug Administration<\/strong><sup><a class=\"text-primary\" href=\"https:\/\/www.fda.gov\/\"><strong>[1]<\/strong><\/a><\/sup>.<\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With the growing improvement and enthusiasm with the combination goods, which has increased the need for multidisciplinary partnerships to be formed within the healthcare industry to adapt to these novel healthcare solutions and with regulators to meet the issues provided by their classification. In the upcoming years, these novel drug-device combos are anticipated to make a significant difference. Researchers believe combination products will benefit people with major illnesses like diabetes, rheumatoid arthritis, multiple sclerosis, cerebral palsy, spinal cord injuries, hepatitis, cancer, and other diseases and ailments.<\/p>\n\n\n\n<p><strong>Also Read<\/strong>: <br><a href=\"https:\/\/corpbiz.io\/learning\/importance-of-a-medical-device-certificate-in-india\/\">What Is The Importance Of A Medical Device Certificate In India?<\/a><br><a href=\"https:\/\/corpbiz.io\/learning\/benefits-of-drug-license-that-you-must-know\/\">Four Prominent Benefits Of Drug License That You Must Know<\/a><br><a href=\"https:\/\/corpbiz.io\/learning\/registration-process-for-medical-devices-in-india\/\">A Step By Step Guide For Registration Process For Medical Devices In India<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Therapeutic and\/or diagnostic goods that combine pharmaceuticals and medical devices are known as &#8220;combination products,&#8221; and their rising complexity has created new regulatory framework issues. A combination product needs to be categorized according to its primary mode of action in order to be sold (PMOA). But with the advancement in the technology and research sector, [&hellip;]<\/p>\n","protected":false},"author":55,"featured_media":53101,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[223],"tags":[3189],"acf":{"service_id":"98"},"authorName":"Soumyadipa Banik","authorImageUrl":"https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2023\/02\/MicrosoftTeams-image-66.jpg","authorDescription":"Soumyadipa is a legal professional and has completed her Masters (L.L.M.) in Business Law from Amity University. She is an aspiring content writer and legal researcher with more than a year experience. She have earlier worked for Startup companies and written business and legal articles, blogs and website content. She is good at presenting complex issues in organized, easy-to-understand terms and committed to provide highly persuasive content.","postViews":2857,"readingTime":8,"_links":{"self":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/53075"}],"collection":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/users\/55"}],"replies":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/comments?post=53075"}],"version-history":[{"count":2,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/53075\/revisions"}],"predecessor-version":[{"id":53077,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/53075\/revisions\/53077"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media\/53101"}],"wp:attachment":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media?parent=53075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/categories?post=53075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/tags?post=53075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}